Jonas Mattsson

List of Publications by Year in Descending Order

193 papers	3,663 citations	33 h-index	53 g-index
219 ext. papers	4,304 ext. citations	3.3 avg, IF	5.08 L-index

#	Paper	IF	Citations
193	Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. *European Journal of Haematology*, **2022**, 108, 61-72	3.8	1
192	Update of Multicenter, Retrospective Evaluation of Overall Response and Failure Free Survival Following Ruxolitinib Therapy for Heavily Pre-Treated Chronic Gvhd Patients with Steroid-Failure: A Proposal of Risk Score Model for Failure-Free Survival. *Blood*, **2021**, 138, 3905-3905	2.2	
191	Single Centre, Retrospective Analysis of Extracorporeal Photopheresis (ECP) Therapy in the Patients Who Are Heavily Pre-Treated for Steroid Resistant Chronic Graft-Versus-Host Disease (GVHD). *Blood*, **2021**, 138, 1806-1806	2.2	
190	Propensity Score Matching Analysis Comparing Extracorporeal Photopheresis (ECP) Vs Best Available Therapy in Third Line or Later Treatment of Chronic Graft-Versus-Host Disease (cGVHD). *Blood*, **2021**, 138, 3896-3896	2.2	
189	A Novel CD34-Specific T-Cell Engager Efficiently Depletes Stem Cells and Acute Myeloid Leukemia Cells in Vitro and In Vivo. *Blood*, **2021**, 138, 2861-2861	2.2	1
188	Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults. *Blood*, **2021**, 138, 110-110	2.2	
187	Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. *Annals of Hematology*, **2021**, 100, 1311-1319	3	
186	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. *Bone Marrow Transplantation*, **2021**, 56, 1908-1918	4.4	2
185	Mesothelin-Specific CAR T Cells Target Ovarian Cancer. *Cancer Research*, **2021**, 81, 3022-3035	10.1	5
184	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. *Transplantation and Cellular Therapy*, **2021**, 27, 428.e1-428.e9		1
183	Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2021**, 56, 2471-2476	4.4	2
182	Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. *European Journal of Haematology*, **2021**, 107, 354-363	3.8	0
181	Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. *European Journal of Haematology*, **2021**, 107, 517-528	3.8	0
180	Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Acta Haematologica*, **2021**, 144, 66-73	2.7	2
179	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2021**, 56, 60-69	4.4	10
178	Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. *Bone Marrow Transplantation*, **2021**, 56, 689-691	4.4	1
177	Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. *European Journal of Haematology*, **2021**, 106, 32-39	3.8	6

176	Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy. *Stem Cell Reviews and Reports*, **2021**, 17, 63-70	7.3	3
175	Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis. *Oral Diseases*, **2021**, 27, 1217-1225	3.5	2
174	Prolactin, a potential biomarker for chronic GVHD activity. *European Journal of Haematology*, **2021**, 106, 158-164	3.8	1
173	Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease. *European Journal of Health Economics*, **2021**, 22, 169-180	3.6	1
172	Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option. *American Journal of Hematology*, **2021**, 96, 179-187	7.1	6
171	Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation. *Hematology/ Oncology and Stem Cell Therapy*, **2021**, 14, 134-140	2.7	0
170	Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study. *Bone Marrow Transplantation*, **2021**, 56, 807-817	4.4	
169	Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level. *Annals of Hematology*, **2021**, 100, 789-798	3	2
168	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. *Transplantation and Cellular Therapy*, **2021**, 27, 600.e1-600.e8		2
167	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. *Leukemia and Lymphoma*, **2021**, 1-11	1.9	0
166	Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. *European Journal of Haematology*, **2021**, 106, 508-519	3.8	
165	Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. *Annals of Hematology*, **2020**, 99, 1377-1387	3	3
164	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1511-1519	4.7	1
163	Posttransplantation Lymphoproliferative Disease Treated by Retransplantation. *Case Reports in Immunology*, **2020**, 2020, 9403123	1.9	1
162	Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. *European Journal of Haematology*, **2020**, 105, 24-29	3.8	1
161	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. *Bone Marrow Transplantation*, **2020**, 55, 1773-1783	4.4	14
160	Multicenter evaluation of parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. *American Journal of Transplantation*, **2020**, 20, 2198-2205	8.7	8
159	Incidence, Outcomes and Predictors of Acute Kidney Injury Post Allogeneic Stem Cell Transplant. *Blood*, **2020**, 136, 16-17	2.2	0

158	Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation. *Clinical and Translational Science*, **2020**, 13, 293-300	4.9	3
157	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. *European Journal of Haematology*, **2020**, 104, 36-45	3.8	2
156	Treatment of radiculomyelopathy in two patients with placenta-derived decidua stromal cells. *International Journal of Hematology*, **2020**, 111, 591-594	2.3	2
155	Allogeneic stem cell transplant in myelodysplastic syndrome-factors impacting survival. *European Journal of Haematology*, **2020**, 104, 116-124	3.8	4
154	Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. *OncoImmunology*, **2020**, 9, 1792058	7.2	14
153	Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c Expression in Tumor. *Advances in Therapy*, **2020**, 37, 5023-5031	4.1	2
152	Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review. *Expert Review of Hematology*, **2020**, 13, 1119-1130	2.8	1
151	Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin Proteins. *Journal of Immunology Research*, **2020**, 2020, 7375947	4.5	2
150	High incidence but low mortality of EBV-reactivation and PTLD after alloHCT using ATG and PTCy for GVHD prophylaxis. *Leukemia and Lymphoma*, **2020**, 61, 3198-3208	1.9	3
149	Diagnostic disagreement between clinical standard histopathological- and retrospective assessment of histopathology-based gastrointestinal graft-versus-host disease in children. *Pediatric Transplantation*, **2020**, 24, e13824	1.8	1
148	Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. *European Journal of Haematology*, **2019**, 103, 510-518	3.8	10
147	Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment. *European Journal of Haematology*, **2019**, 103, 483-490	3.8	4
146	Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors. *Immunotherapy*, **2019**, 11, 335-345	3.8	28
145	Effect of Graft-versus-Host Disease Prophylaxis Regimens on T and B Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1260-1268	4.7	11
144	Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1965-1969	4.7	7
143	Combination of the Centre for International Blood and Marrow Transplant Registry Risk Score and the Global Severity Score Enhances Prognostic Risk Stratification in Patients Receiving Frontline Therapy for Chronic Graft-versus-Host Disease. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1761-1769	4.7	1
142	Higher response rates in patients with severe chronic skin graft-versus-host disease treated with extracorporeal photopheresis. *Central-European Journal of Immunology*, **2019**, 44, 84-91	1.6	5
141	Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. *Expert Opinion on Biological Therapy*, **2019**, 19, 811-827	5.4	15

140	The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease. *Clinical Transplantation*, **2019**, 33, e13537	3.8	2
139	A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. *Expert Review of Hematology*, **2019**, 12, 311-323	2.8	10
138	Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status. *Expert Review of Hematology*, **2019**, 12, 295-309	2.8	6
137	T-cell frequencies of CD8 and CD27 cells in the stem cell graft predict the outcome after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2019**, 54, 1562-1574	4.4	10
136	Individualization of Hematopoietic Stem Cell Transplantation Using Alpha/Beta T-Cell Depletion. *Frontiers in Immunology*, **2019**, 10, 189	8.4	5
135	Epstein-Barr virus associated post-transplant lymphoproliferative disorder mimicking acute graft versus host disease. *European Journal of Haematology*, **2019**, 103, 519-522	3.8	1
134	Granulocyte transfusions could benefit patients with severe oral mucositis after allogeneic hematopoietic stem cell transplantation. *Vox Sanguinis*, **2019**, 114, 769-777	3.1	3
133	Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis. *European Journal of Haematology*, **2019**, 103, 597-606	3.8	6
132	The Metabolic Profile of Tumor and Virally Infected Cells Shapes Their Microenvironment Counteracting T Cell Immunity. *Frontiers in Immunology*, **2019**, 10, 2309	8.4	9
131	Pilot Study on Frailty and Functionality on Routine Clinical Assessment in Allogeneichematopoietic Cell Transplantation to Predict Outcomes. *Blood*, **2019**, 134, 380-380	2.2	3
130	Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia. *Blood*, **2019**, 134, 5725-5725	2.2	1
129	Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft--Host Disease Prophylaxis. *Clinical Hematology International*, **2019**, 1, 105-113	1.8	14
128	Dual T-Cell Depletion with a Very Low Dose of ATG and Ptcy Provides an Effective Control of Acute Gvhd in PBSC RIC Allo-HSCT. *Blood*, **2019**, 134, 5669-5669	2.2	
127	Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. *Blood*, **2019**, 134, 3344-3344	2.2	
126	Patient Age and Donor HLA Matching Can Stratify Allogeneic Hematopoietic Cell Transplantation (HCT) Patients into Prognostic Groups: A Collaborative Study. *Blood*, **2019**, 134, 3341-3341	2.2	
125	The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. *Blood*, **2019**, 134, 3299-3299	2.2	
124	Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. *Blood*, **2019**, 134, 4590-4590	2.2	
123	Outcomes of Therapy Related Acute Lymphoblastic Leukemia in Adults after Allogeneic Stem Cell Transplantation - Twenty-Year Experience from a Tertiary Care Center. *Blood*, **2019**, 134, 5717-5717	2.2	

122	Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre. *Blood*, **2019**, 134, 5737-5737	2.2	
121	Impact of Hematopoeitic Cell Transplantation-Co-Morbidity Index (HCT-CI) and Its Individual Components on Allogeneic Transplant Outcomes. *Blood*, **2019**, 134, 5722-5722	2.2	
120	No Impact of Donor♀ Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient. *Blood*, **2019**, 134, 4514-4514	2.2	
119	Improved Gvhd Free, Relapse Free Survival Using Dual T-Cell Depletion with ATG and Ptcy in Matched Unrelated Donor RIC Allo-HSCT. *Blood*, **2019**, 134, 4594-4594	2.2	
118	The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Diseases Is Influenced by HLA Match, Year of Transplantation, and Immunized Female Donor. *Transplantation*, **2019**, 103, 1247-1252	1.8	1
117	Pre-formulation investigations for establishing a protocol for treosulfan handling and activation. *Pharmaceutical Development and Technology*, **2019**, 24, 639-648	3.4	
116	Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 720-727	4.7	32
115	Norovirus causing severe gastrointestinal disease following allogeneic hematopoietic stem cell transplantation: A retrospective analysis. *Transplant Infectious Disease*, **2018**, 20, e12847	2.7	7
114	Risk Factors for Severe Acute Graft-versus-Host Disease in Donor Graft Composition. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 467-477	4.7	10
113	Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. *International Journal of Hematology*, **2018**, 107, 478-485	2.3	8
112	The effect of N-acetyl-l-cysteine (NAC) on liver toxicity and clinical outcome after hematopoietic stem cell transplantation. *Scientific Reports*, **2018**, 8, 8293	4.9	6
111	Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells. *Cytotherapy*, **2018**, 20, 941-951	4.8	9
110	Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 677-683	4.7	9
109	A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. *Journal of Immunotherapy*, **2017**, 40, 132-139	5	4
108	No effect of HLA-C mismatch after allogeneic hematopoietic stem cell transplantation with unrelated donors and T-cell depletion in patients with hematological malignancies. *Clinical Transplantation*, **2017**, 31, e13012	3.8	
107	Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation. *International Journal of Hematology*, **2017**, 106, 471-475	2.3	8
106	Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease. *Frontiers in Immunology*, **2017**, 8, 717	8.4	23
105	Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. *PLoS ONE*, **2017**, 12, e0187294	3.7	10

104	Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. *Oncotarget*, **2017**, 8, 60257-60269	3.3	8
103	A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. *Haematologica*, **2016**, 101, 1417-1425	6.6	41
102	Risk Factors for Invasive Mold Infections and Implications for Choice of Prophylaxis after Allogeneic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1684-1689	4.7	8
101	Community Acquired Respiratory Viral Infections (CARV) in Patients with Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Recipients. *Biology of Blood and Marrow Transplantation*, **2016**, 22, S178	4.7	78
100	Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 676-681	4.7	8
99	Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes. *Oncotarget*, **2016**, 7, 23581-93	3.3	26
98	Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. *Journal of Immunology Research*, **2016**, 2016, 5601204	4.5	10
97	Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?. *PLoS ONE*, **2016**, 11, e0154737	3.7	17
96	Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation - A comparison of the last two decades. *Pediatric Transplantation*, **2016**, 20, 667-74	1.8	19
95	Reply to: transient grades three to four acute hepatitis is a common complication of rabbit antithymocyte globulin (thymoglobulin) administered before allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1145-6	4.7	1
94	Transplanted Bone Marrow-Derived Cells Contribute to Human Adipogenesis. *Cell Metabolism*, **2015**, 22, 408-17	24.6	61
93	General health, symptom occurrence, and self-efficacy in adult survivors after allogeneic hematopoietic stem cell transplantation: a cross-sectional comparison between hospital care and home care. *Supportive Care in Cancer*, **2015**, 23, 1273-83	3.9	12
92	Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. *Haematologica*, **2015**, 100, 1477-85	6.6	26
91	Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation. *Transfusion*, **2015**, 55, 2339-50	2.9	13
90	Effect of Total Nucleated and CD34(+) Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 889-93	4.7	67
89	Placenta-Derived Decidual Stromal Cells for Graft-Versus-Host Disease, Hemorrhaging, and Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, S149	4.7	5
88	T-cell receptor excision circle levels after allogeneic stem cell transplantation are predictive of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome. *Stem Cells and Development*, **2014**, 23, 1559-67	4.4	7
87	Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 135-8	4.7	39

86	Reduced IL-7 responsiveness defined by signal transducer and activator of transcription 5 phosphorylation in T cells may be a marker for increased risk of developing cytomegalovirus disease in patients after hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 128-32	4.7	4
85	Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 264-71	4.7	28
84	Expanded umbilical cord blood T cells used as donor lymphocyte infusions after umbilical cord blood transplantation. *Cytotherapy*, **2014**, 16, 1528-1536	4.8	15
83	Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1777-84	4.7	40
82	Posaconazole concentrations in human tissues after allogeneic stem cell transplantation. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 4941-3	5.9	16
81	Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1646-9	4.7	23
80	Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. *Haematologica*, **2014**, 99, 346-52	6.6	114
79	Allogeneic Hematopoietic Cell Transplantation for GATA2 Deficiency in a Patient With Disseminated Human Papillomavirus Disease. *Transplantation*, **2014**, 98, e95-6	1.8	12
78	Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital. *Pediatric Transplantation*, **2014**, 18, 398-404	1.8	7
77	Novel method to characterize immune cells from human prostate tissue. *Prostate*, **2014**, 74, 1391-9	4.2	9
76	Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate. *Clinical Drug Investigation*, **2014**, 34, 43-52	3.2	5
75	Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation. *PLoS ONE*, **2014**, 9, e86619	3.7	7
74	Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Intensity. *Blood*, **2014**, 124, 2537-2537	2.2	
73	Busulphan Metabolism Via Flavin-Containing Monooxygenase 3 (FMO3) Can Explain Several Interactions with Other Drugs. *Blood*, **2014**, 124, 1150-1150	2.2	
72	Systems level immune response analysis and personalized medicine. *Expert Review of Clinical Immunology*, **2013**, 9, 307-17	5.1	7
71	Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 314-20	4.7	19
70	Chimerism patterns of long-term stable mixed chimeras posthematopoietic stem cell transplantation in patients with nonmalignant diseases: follow-up of long-term stable mixed chimerism patients. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 838-44	4.7	28
69	Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. *Stem Cells*, **2013**, 31, 592-601	5.8	73

68	Hospital care or home care after allogeneic hematopoietic stem cell transplantation--patientsQ experiences of care and support. *European Journal of Oncology Nursing*, **2013**, 17, 389-95	2.8	17
67	Cord blood T cells cultured with IL-7 in addition to IL-2 exhibit a higher degree of polyfunctionality and superior proliferation potential. *Journal of Immunotherapy*, **2013**, 36, 432-41	5	11
66	A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. *Clinical Transplantation*, **2013**, 27, E368-74	3.8	41
65	Chimerism and use of mesenchymal stem cells in umbilical cord blood transplantation. *Chimerism*, **2013**, 4, 34-5		1
64	Graft Failure In Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2013**, 122, 4559-4559	2.2	
63	Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. *European Journal of Haematology*, **2012**, 89, 220-7	3.8	57
62	Effects of different serum-levels of ATG after unrelated donor umbilical cord blood transplantation. *Transplant Immunology*, **2012**, 27, 59-62	1.7	23
61	Major surgery in a neutropenic patient undergoing allogeneic stem cell transplantation for high risk myelofibrosis. *International Journal of Hematology*, **2012**, 96, 798-800	2.3	1
60	Mesenchymal stem cells inhibit thymic reconstitution after allogeneic cord blood transplantation. *Stem Cells and Development*, **2012**, 21, 1409-17	4.4	24
59	Thymic function after allogeneic stem cell transplantation is dependent on graft source and predictive of long term survival. *Clinical Immunology*, **2012**, 142, 343-50	9	26
58	Expansion of T-cells from the cord blood graft as a predictive tool for complications and outcome of cord blood transplantation. *Clinical Immunology*, **2012**, 143, 134-44	9	3
57	Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. *Clinical Infectious Diseases*, **2012**, 55, 1064-73	11.6	99
56	Update on viral infections in lung transplantation. *Current Opinion in Pulmonary Medicine*, **2012**, 18, 264-70	3	14
55	Factors with an impact on chimerism development and long-term survival after umbilical cord blood transplantation. *Transplantation*, **2012**, 94, 1066-74	1.8	19
54	Donor lymphocyte infusion may reduce the incidence of bronchiolitis obliterans after allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 1214-21	4.7	9
53	Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 1688-97	4.7	106
52	Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation. *Transplant Immunology*, **2011**, 25, 153-8	1.7	18
51	Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure. *Clinical Transplantation*, **2011**, 25, E68-76	3.8	30

50	Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders. *European Journal of Haematology*, **2011**, 87, 503-9	3.8	19
49	Improved Survival with Ursodeoxycholic Acid Prophylaxis in Allogeneic Stem Cell Transplantation: Long-Term Follow-up of a Randomized Study of the Nordic Bone Marrow Transplantation Group. *Blood*, **2011**, 118, 488-488	2.2	
48	Stable mixed double donor chimerism: Absence of war doesn't necessarily mean peace. *Chimerism*, **2010**, 1, 64-5		3
47	Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 1728-37	4.7	20
46	Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. *Transplantation*, **2010**, 90, 1022-9	1.8	25
45	Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation. *Journal of Immunotherapy*, **2010**, 33, 96-105	5	24
44	A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. *Cancer Immunology, Immunotherapy*, **2010**, 59, 473-7	7.4	67
43	C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation. *International Journal of Hematology*, **2010**, 92, 161-7	2.3	13
42	GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants. *European Journal of Haematology*, **2010**, 84, 323-31	3.8	13
41	Stable mixed donor-donor chimerism after double cord blood transplantation. *International Journal of Hematology*, **2009**, 90, 526-531	2.3	14
40	Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation. *Transplantation*, **2009**, 87, 467-72	1.8	2
39	Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. *Transplantation*, **2009**, 88, 1222-6	1.8	75
38	Norovirus Infections in Patients with Hematological Diseases and After Stem Cell Transplantation; Epidemiological and Clinical Aspects.. *Blood*, **2009**, 114, 2661-2661	2.2	
37	Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. *European Journal of Haematology*, **2008**, 80, 419-28	3.8	16
36	Graft failure after allogeneic hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 165-70	4.7	133
35	Case-control comparison of at-home and hospital care for allogeneic hematopoietic stem-cell transplantation: the role of oral nutrition. *Transplantation*, **2008**, 85, 1000-7	1.8	33
34	Novel antibodies to the donor stem cell population CD34+/VEGFR-2+ are associated with rejection after hematopoietic stem cell transplantation. *Transplantation*, **2008**, 86, 686-96	1.8	19
33	Recent progress in allogeneic stem cell transplantation. *Current Opinion in Molecular Therapeutics*, **2008**, 10, 343-9		11

32	Hemorrhagic cystitis: a retrospective single-center survey. *Clinical Transplantation*, **2007**, 21, 659-67	3.8	45
31	Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 675-82	4.7	52
30	Prospecitve Quantitative PCR Monitoring of Allogeneic Stem Cell Transplant (SCT) Patients at High Risk for EBV Associated PTLD.. *Blood*, **2007**, 110, 2969-2969	2.2	
29	Decreasing mortality rate in early pneumonia following hematopoietic stem cell transplantation. *Scandinavian Journal of Infectious Diseases*, **2006**, 38, 970-6		25
28	Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center. *Transplantation*, **2006**, 81, 718-25	1.8	51
27	Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. *Transplantation*, **2006**, 82, 913-9	1.8	45
26	Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2005**, 11, 280-7	4.7	32
25	Identification of maternal hematopoietic cells in a 2nd-trimester fetus. *Fetal Diagnosis and Therapy*, **2005**, 20, 355-8	2.4	20
24	Decreased serum levels of clara cell secretory protein (CC16) are associated with bronchiolitis obliterans and may permit early diagnosis in patients after allogeneic stem-cell transplantation. *Transplantation*, **2005**, 79, 1411-6	1.8	32
23	Molecular monitoring of T-cell chimerism early after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades II-IV. *Clinical Transplantation*, **2005**, 19, 346-9	3.8	13
22	Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. *Biology of Blood and Marrow Transplantation*, **2004**, 10, 195-203	4.7	42
21	Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors. *Biology of Blood and Marrow Transplantation*, **2004**, 10, 877-82	4.7	17
20	A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. *Transplantation*, **2004**, 78, 1014-20	1.8	54
19	No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study. *Transplantation*, **2004**, 78, 101-6	1.8	138
18	Increased immune transcript levels are correlated with acute graft-versus-host disease and cytomegalovirus response after allogeneic stem cell transplantation. *Transplantation*, **2004**, 77, 195-200	1.8	9
17	Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. *Transplantation*, **2004**, 78, 122-7	1.8	100
16	Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans. *Transplantation*, **2003**, 75, 1061-6	1.8	14
15	Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. *Blood*, **2003**, 101, 469-72	2.2	42

14	Serum levels of cytokines correlate to donor chimerism and acute graft-vs.-host disease after haematopoietic stem cell transplantation. *European Journal of Haematology*, **2003**, 70, 384-91	3.8	43
13	Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. *British Journal of Haematology*, **2003**, 122, 788-94	4.5	38
12	Prenatal T-cell reconstitution after in utero transplantation with fetal liver cells in a patient with X-linked severe combined immunodeficiency. *American Journal of Obstetrics and Gynecology*, **2002**, 187, 475-82	6.4	83
11	The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation. *British Journal of Haematology*, **2002**, 119, 1133-6	4.5	39
10	Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2002**, 8, 674-82	4.7	79
9	Clinical tolerance after allogeneic hematopoietic stem cell transplantation: a study of influencing factors. *Transplantation*, **2002**, 73, 930-6	1.8	7
8	The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. *Blood*, **2001**, 98, 1982-4	2.2	78
7	Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. *British Journal of Haematology*, **2001**, 115, 935-44	4.5	52
6	Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. *Pediatric Transplantation*, **2001**, 5, 285-92	1.8	18
5	An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation. *European Journal of Haematology*, **2001**, 66, 50-6	3.8	13
4	T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. *Transplantation*, **2001**, 71, 433-9	1.8	78
3	Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. *Transplantation*, **2000**, 69, 2043-8	1.8	27
2	Improved survival after bone marrow transplantation for early leukemia using busulfan-cyclophosphamide and individualized prophylaxis against graft-versus-host disease: a long-term follow-up. *Clinical Transplantation*, **1999**, 13, 512-9	3.8	14
1	Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. *Transplantation*, **1998**, 66, 1330-4	1.8	129